EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials

Stephen D Silberstein, Hans-Christoph Diener, David W Dodick iD, Katherine Sommer, Richard B Lipton iD

Headache: The Journal of Head and Face Pain · 2024

DOI: 10.1111/head.14743 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Headache: The Journal of Head and Face Pain, 2024. Verfasst von Stephen D Silberstein und 4 weiteren Autor:innen. Beteiligte Einrichtung: Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Migraine Disorders. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective To characterize the long‐term (56‐week) benefits of continuous onabotulinumtoxinA treatment response in individuals with chronic migraine (CM) who achieved reduction to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type AMigraine DisordersHumansAdultMaleFemaleDouble-Blind MethodMiddle AgedChronic DiseaseNeuromuscular AgentsQuality of LifeOutcome Assessment, Health Care

Stichwörter der Autor:innen

botulinum toxin type Aheadachepatient‐reported outcome measuresquality of life

Substanzen

Botulinum Toxins, Type Aonabotulinum toxin ANeuromuscular Agents

Autor:innen und Institutionen

  • Jefferson Headache Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Department of Neuroepidemiology, Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Essen, Germany.
  • Department of Neurology, Mayo Clinic, Phoenix, Arizona, USA.
  • Atria Academy of Science and Medicine, New York, New York, USA.
  • Allergan, an AbbVie Company, Irvine, California, USA.
  • Department of Neurology, Montefiore Headache Center, Albert Einstein College of Medicine, Bronx, New York, USA.

ORCID-Profile: David W Dodick, Richard B Lipton

Förderung

  • AbbVie

Zitieren

APA

Silberstein, S. D., Diener, H. C., Dodick, D. W., Sommer, K., & Lipton, R. B. (2024). Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/head.14743

Vancouver

Silberstein SD, Diener HC, Dodick DW, Sommer K, Lipton RB. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials. Headache: The Journal of Head and Face Pain. 2024. doi:10.1111/head.14743

BibTeX
@article{Silberstein2024,
  author = {Silberstein, Stephen D and Diener, Hans-Christoph and Dodick, David W and Sommer, Katherine and Lipton, Richard B},
  title = {Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2024},
  doi = {10.1111/head.14743}
}
Kostenlos starten →